Interleukin-23 (IL-23) is a pro-inflammatory cytokine composed of two subunits, IL-23A (p19) and IL-12/23B (p40), the latter shared with Interleukin-12 (IL-12). IL-23 is mainly produced by macrophages and dendritic cells, in response to exogenous or endogenous signals, and drives the differentiation and activation of T helper 17 (Th17) cells with subsequent production of IL-17A, IL-17F, IL-6, IL-22, and tumor necrosis factor α (TNF-α). Although IL-23 plays a pivotal role in the protective immune response to bacterial and fungal infections, its dysregulation has been shown to exacerbate chronic immune-mediated inflammation. Well-established experimental data support the concept that IL-23/IL-17 axis activation contributes to the development of several inflammatory diseases, such as PsA, Psoriasis, Psoriatic Arthritis; AS, Ankylosing Spondylitis; IBD, Inflammatory Bowel Disease; RA, Rheumatoid Arthritis; SS, Sjogren Syndrome; MS, Multiple Sclerosis. As a result, emerging clinical studies have focused on the blockade of this pathogenic axis as a promising therapeutic target in several autoimmune disorders; nevertheless, a greater understanding of its contribution still requires further investigation. This review aims to elucidate the most recent studies and literature data on the pathogenetic role of IL-23 and Th17 cells in inflammatory rheumatic diseases.

Schinocca C., Rizzo C., Fasano S., Grasso G., La Barbera L., Ciccia F., et al. (2021). Role of the IL-23/IL-17 Pathway in Rheumatic Diseases: An Overview. FRONTIERS IN IMMUNOLOGY, 12, 637829 [10.3389/fimmu.2021.637829].

Role of the IL-23/IL-17 Pathway in Rheumatic Diseases: An Overview

Schinocca C.
Primo
Membro del Collaboration Group
;
Rizzo C.
Membro del Collaboration Group
;
Ciccia F.
Membro del Collaboration Group
;
Guggino G.
Ultimo
Membro del Collaboration Group
2021-02-22

Abstract

Interleukin-23 (IL-23) is a pro-inflammatory cytokine composed of two subunits, IL-23A (p19) and IL-12/23B (p40), the latter shared with Interleukin-12 (IL-12). IL-23 is mainly produced by macrophages and dendritic cells, in response to exogenous or endogenous signals, and drives the differentiation and activation of T helper 17 (Th17) cells with subsequent production of IL-17A, IL-17F, IL-6, IL-22, and tumor necrosis factor α (TNF-α). Although IL-23 plays a pivotal role in the protective immune response to bacterial and fungal infections, its dysregulation has been shown to exacerbate chronic immune-mediated inflammation. Well-established experimental data support the concept that IL-23/IL-17 axis activation contributes to the development of several inflammatory diseases, such as PsA, Psoriasis, Psoriatic Arthritis; AS, Ankylosing Spondylitis; IBD, Inflammatory Bowel Disease; RA, Rheumatoid Arthritis; SS, Sjogren Syndrome; MS, Multiple Sclerosis. As a result, emerging clinical studies have focused on the blockade of this pathogenic axis as a promising therapeutic target in several autoimmune disorders; nevertheless, a greater understanding of its contribution still requires further investigation. This review aims to elucidate the most recent studies and literature data on the pathogenetic role of IL-23 and Th17 cells in inflammatory rheumatic diseases.
22-feb-2021
Schinocca C., Rizzo C., Fasano S., Grasso G., La Barbera L., Ciccia F., et al. (2021). Role of the IL-23/IL-17 Pathway in Rheumatic Diseases: An Overview. FRONTIERS IN IMMUNOLOGY, 12, 637829 [10.3389/fimmu.2021.637829].
File in questo prodotto:
File Dimensione Formato  
Role of the IL23IL17 Pathway in Rheumatic Diseases An Overview.pdf

accesso aperto

Tipologia: Versione Editoriale
Dimensione 643.98 kB
Formato Adobe PDF
643.98 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/536445
Citazioni
  • ???jsp.display-item.citation.pmc??? 97
  • Scopus 181
  • ???jsp.display-item.citation.isi??? 174
social impact